BioNTech (BNTX) Stock Movement Summary BioNTech shares fell following a downgrade by Leerink Partners. The brokerage downgraded BNTX from "outperform" to "market perform" and set a $113 price target. Leerink cited a recent 24% share rally as the reason for the downgrade, stating the stock has risen to align with its discounted cash flow valuation. The firm noted limited clinical data readouts are expected until 2027 and identified diminished upside from cancer vaccine programs. Leerink maintains a positive long-term view of BioNTech's oncology strategy, including pumitamig. The downgrade reflects expectations of near-term volatility rather than a negative outlook on the company's long-term prospects.
Read full analysisBioNTech (BNTX) Stock Movement Summary BioNTech shares fell following a downgrade by Leerink Partners. The brokerage downgraded BNTX from "outperform" to "market perform" and set a $113 price target. Leerink cited a recent 24% share rally as the reason for the downgrade, stating the stock has risen to align with its discounted cash flow valuation. The firm noted limited clinical data readouts are expected until 2027 and identified diminished upside from cancer vaccine programs. Leerink maintains a positive long-term view of BioNTech's oncology strategy, including pumitamig. The downgrade reflects expectations of near-term volatility rather than a negative outlook on the company's long-term prospects.
BioNTech SE (BNTX) is a publicly traded company in the Broad Market sector.